Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Predicted activity of UGT2B7, ABCB1, OPRM1, and COMT using full-gene haplotypes and their association with the CYP2D6-inferred metabolizer phenotype.

Forensic science international. Genetics - 1 Mar 2018

Wendt Frank R, Sajantila Antti, Budowle Bruce

Abstract excerpt

The pharmacogene, CYP2D6, is commonly used to infer metabolizer phenotype of many marketed drugs and endogenous toxins in ante- and post-mortem patients but only represents the efficiency of phase 1 metabolism. Downstream metabolic enzymes encoded by UGT2B7, ABCB1, OPRM1, and COMT also have been implicated in variable individual response to drugs due to their activity at different stages of the tramadol ADME...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to ATP Binding Cassette Transporter, Subfamily B
Share to Catechol O-Methyltransferase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2D6

Share to Genetics, Population

Share to Glucuronosyltransferase

Share to Haplotypes

Share to Pharmacogenetics

Share to Receptors, Opioid, mu

Source

Identifiers

PMID: 29190510
DOI: 10.1016/j.fsigen.2017.11.012

Genes

ABCB1
COMT
OPRM1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Predicted activity of UGT2B7, ABCB1, OPRM1, and COMT using full-gene haplotypes and their association with the CYP2D6-inferred metabolizer phenotype.PMID 29190510Read ↗

Full-gene haplotypes refine CYP2D6 metabolizer phenotype inferences.Semantic proximity Read ↗

A Review of the Important Role of CYP2D6 in Pharmacogenomics.Semantic proximity Read ↗

Outcomes and Clinical Relevance of a 16-Gene Pharmacogenetic Panel Test for Medication Management - A Cohort Study in 135 PatientsSemantic proximity Read ↗

Interethnic variability of CYP2D6 alleles and of predicted and measured metabolic phenotypes across world populations.Semantic proximity Read ↗

Clinical Pharmacology and Pharmacogenetics in a Genomics Era: The DMET PlatformSemantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy.Semantic proximity Read ↗

Complexities of CYP2D6 gene analysis and interpretation.Semantic proximity Read ↗

CYP2D6 pharmacogenomicsSemantic proximity Read ↗

PharmGKB summary: very important pharmacogene information for CYP2B6.Semantic proximity Read ↗

Fundamental Considerations for GeneticallyGuided Pain Management with Opioids Based on CYP2D6 and OPRM1 PolymorphismsSemantic proximity Read ↗

Meta-analysis of probability estimates of worldwide variation of CYP2D6 and CYP2C19.Semantic proximity Read ↗

Pharmacogenetic screening for drug therapy: from single gene markers to decision making in the next generation sequencing era.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.